Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million
Stockholm, Sweden - August 28, 2023 – Biosergen AB ("Biosergen" or the “Company") today announces the outcome of the exercise of warrants series TO2, which were issued in connection with the Company’s rights issue of units on Nasdaq First North Growth Market in October 2022. In total, 8,258,203 warrants series TO2, corresponding to approximately 96.1 percent of the total number of outstanding warrants series TO2, were exercised for subscription of 8,258,203 shares at an exercise price of SEK 0.66 per share. Biosergen will thereby receive approximately SEK 5.5 million before issuing costs.
The exercise period for exercise of the warrants series TO2 took place during the period from and including August 14, 2023, up to and including August 25, 2023. The exercise price per share was set to SEK 0.66 and each warrant series TO2 entitled to subscription of one (1) new share in the Company.
In total, 8,258,203 warrants series TO2 were exercised for subscription of the same number of shares, meaning that approximately 96.1 percent of all outstanding warrants series TO2 were exercised for subscription of shares. Through the warrant exercise, Biosergen receives approximately SEK 5.5 million before issuing costs.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants series TO2, the number of shares in Biosergen increases by 8,258,203 shares, from 42,427,660 shares to a total of 50,685,863 shares. The share capital increases by SEK 206,455.075, from SEK 1,060,691.500 to SEK 1,267,146.575.
For existing shareholders who did not exercise any warrants series TO2, the dilution amounts to approximately 16.3 percent calculated on the number of shares and votes in the Company before the warrant exercise.
Advisors
Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Niels Lauren, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net
Certified Adviser
Erik Penser Bank
Telephone: +46 8 463 8000
E-mail: certifiedadvisor@penser.se
ABOUT BIOSERGEN
Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005’s potential as a game-changing antifungal treatment. Biosergen’s development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Biosergen. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Biosergen has only taken place through the prospectus that Biosergen published on September 13, 2022.
This information is information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact person's agency, at 15:25 CEST on August 28, 2023.